Clostridium difficile in inflammatory bowel disease

• Main Authors: O V Knyazev, A V Kagramanova, M E Chernova, I A Korneeva, A I Parfenov
• Format: Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 2018-11-01
• Series: Терапевтический архив
• Subjects: inflammatory bowel disease; clostridium infection
• Online Access: https://ter-arkhiv.ru/0040-3660/article/viewFile/32863/pdf
• ISSN: 0040-3660; 2309-5342

Aim. To study epidemiology and risk factors for Clostridium infection (CDI) associated with Clostridium difficile in patients with inflammatory bowel disease (IBD). Materials and methods. 1179 medical records were analyzed in a retrospective study of patients with IBD, of which 764 patients met the inclusion criteria. Patients were divided into 2 groups based on the presence of a preliminary diagnosis of CDI. Statistical analysis was carried out using Pearson Chi-square and two-sample t-test. Results. The incidence of CDI in patients with IBD was 17.3%, with the same prevalence in patients with Crohn's disease (CD) (n=53/40.1%) and ulcerative colitis (UC) (n=79/59.9%). The mean age of occurrence of CDI in patients with IBD was 37.8±12.9, 84.8% of infections were community-acquired and only 4.5% occurred in medical institutions. Only 21.2% of all patients with CDI had a history of antibiotic use, and 24.2% had previously used steroids. Long-term immunosuppressive therapy in patients with IBD has an impact on the development of CDI: among patients with CDI 45.5% long-term received azathioprine/6-mercaptopurine, in patients without IBD - 17.7% (p